JAGSNPHARM

March 13 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• GOT ORDER FOR TAX DEMAND OF 48.2 MILLION RUPEES

Source text: ID:nBSE6y3GBF

Further company coverage: JGSN.NS

((Reuters.Briefs@thomsonreuters.com;;))

March 12 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• BOARD APPROVES EQUITY SHARE BUYBACK PROPOSAL

• BUYBACK PRICE SET AT 250 RUPEES PER EQUITY SHARE

• MAXIMUM BUYBACK OFFER SIZE IS 400 MILLION RUPEES

Source text: ID:nBSE1dm7FV

Further company coverage: JGSN.NS

((Reuters.Briefs@thomsonreuters.com;))

** Jagsonpal Pharmaceuticals JGSN.NS rises 7.9% to 181.50 rupees

** Co's board to meet on March 12 to consider share buyback

** Trading vols at more than 26x the 30-day average in stock's busiest session since July 28, 2025

** JGSN down 5.8% YTD

(Reporting by Vijay Malkar)

((VijayDattaram.Malkar@thomsonreuters.com;))

March 9 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• BOARD TO CONSIDER SHARE BUYBACK ON MARCH 12, 2026

Source text: ID:nBSE4P0Zv8

Further company coverage: JGSN.NS

((Reuters.Briefs@thomsonreuters.com;;))

**Shares of Jagsonpal Pharmaceuticals JGSN.NS fall for sixth straight session; down 4.6% to 156.9 rupees

**Drugmaker's Q3 net profit slumps 66% to 109.5 million rupees; Q3 revenue falls 1.5% to 729.5 million rupees

**Co recorded a 20.8 million rupees charge after India notified new labour codes, the country's biggest overhaul of workers' laws in decades

**More than 54,854 shares change hands vs 30 day avg of 42,597 shares

**Stock fell 21.2% in 2025

(Reporting by Mridula Kumar in Bengaluru)

((Mridula.Kumar@thomsonreuters.com;))

Dec 30 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• RECEIVES TAX DEMAND ORDER TOTALING 15.2 MILLION RUPEES

Source text: ID:nBSE18JFkx

Further company coverage: JGSN.NS

((Reuters.Briefs@thomsonreuters.com;))

April 2 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• CUSTOMS AUTHORITY PASSES ORDER ON JAGSONPAL PHARMACEUTICALS

• ORDER CONFIRMS DIFFERENTIAL DUTY OF 51 MILLION RUPEES PLUS PENALTY

Source text: ID:nBSE6sHSXM

Further company coverage: JGSN.NS

((Reuters.Briefs@thomsonreuters.com;;))

** Shares of Jagsonpal Pharmaceuticals JGSN.NS slide as much 4.4% to 210.03 rupees, last down 1.1%

** Drugmaker gets U.S. FDA warning letter related to drug listing, establishment registration after plant inspection

** Co estimates sales hit worth 35 mln rupees ($403,960) so far in current fiscal year

** Stock down 10% YTD, it logged five straight years of gains till 2024

($1 = 86.6420 Indian rupees)

(Reporting by Manvi Pant in Bengaluru)

((Manvi.Pant@thomsonreuters.com; +918447554364;))

Feb 21 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• JAGSONPAL PHARMACEUTICALS LTD - TO ACQUIRE RESILIENT COSMECEUTICALS INDIA BUSINESS

• JAGSONPAL PHARMACEUTICALS LTD - DEAL FOR 240 MILLION RUPEES

Source text: ID:nBSE7rdxsm

Further company coverage: JGSN.NS

((reuters.briefs@thomsonreuters.com;))

Feb 5 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• NAMES SACHIN JAIN AS CHIEF FINANCIAL OFFICER

Source text: [ID:]

Further company coverage: JGSN.NS

((Reuters.Briefs@thomsonreuters.com;;))

** Jagsonpal Pharmaceuticals JGSN.NS jumps 7% to 244 rupees

** Co's Q3 profit jumps nearly three-fold, helped by strong sales of gynaecology products

** About 900,000 shares traded in stock's most active session since Dec. 3, 2024

** JGSN marginally up YTD; had risen 57% in 2024

(Reporting by Sethuraman NR in Bengaluru)

((Sethuraman.NR@thomsonreuters.com; (+91 9945291420); Reuters Messaging: nallur.sethuraman.thomsonreuters.com@reuters.net))

Nov 22 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• JAGSONPAL PHARMACEUTICALS - CFO ASHISH LAKHOTIA RESIGNS

Source text: ID:nBSE5Z828b

Further company coverage: JGSN.NS

((Reuters.Briefs@thomsonreuters.com;))

Nov 19 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• JAGSONPAL PHARMACEUTICALS - GOT 410 MILLION RUPEES TOWARDS SALE OF CO'S FARIDABAD FACILITY

Source text: ID:nNSE6311kK

Further company coverage: JGSN.NS

((Reuters.Briefs@thomsonreuters.com;))

** Shares of Jagsonpal Pharmaceuticals Ltd JGSN.NS rise as much as 5.6% to 499.80 rupees

** Pharma co reported 53.4% y/y rise in Q2 profit to 114.6 mln rupees ($1.4 mln); rev jumped 29.2%

** Board also approved sub division of shares

** Stock on track to gain for 5th straight month; gained 18.3% so far this month

** More than 163,000 shares traded as of 10:13 a.m. IST, vs their 30-day moving avg of 89,502 shares

** JGSN last up 3.5%, adding to YTD gains of 26% so far

($1 = 84.0650 Indian rupees)

(Reporting by Meenakshi Maidas in Bengaluru)

((meenakshi.maidas@thomsonreuters.com;))

Oct 23 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• JAGSONPAL PHARMACEUTICALS LTD - APPROVED SUB-DIVISION OF SHARES

Source text for Eikon: ID:nBSE1mV11V

Further company coverage: JGSN.NS

((Reuters.Briefs@thomsonreuters.com;))

May 24 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• LAUNCHES MEMUP, A BIOIDENTICAL HORMONE REPLACEMENT THERAPY

Source text for Eikon: ID:nBSE7hQtsH

Further company coverage: JGSN.NS

((reuters.briefs@thomsonreuters.com;))

March 8 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• LAUNCHES QUEEZY-ER®

• QUEEZY-ER® PROVIDING RELIEF FROM NAUSEA AND VOMITING IN PREGNANCY

Source text for Eikon: [ID:]

Further company coverage: JGSN.NS

((Reuters.Briefs@thomsonreuters.com;))

May 23 (Reuters) - Jagsonpal Pharmaceuticals Ltd JGSN.NS:

• DIVIDEND OF 5 RUPEES PER SHARE

• MARCH-QUARTER NET PROFIT 56 MILLION RUPEES VERSUS PROFIT 3.1 MILLION RUPEES

• MARCH-QUARTER REVENUE FROM OPERATIONS 554.5 MILLION RUPEES VERSUS 512.3 MILLION RUPEES

Source text for Eikon: ID:nBSE7Q3W2k

Further company coverage: JGSN.NS

((Reuters.Briefs@thomsonreuters.com;))